Tetraphase stock plummets on antibiotic failure
Tetraphase Pharmaceuticals saw its stock plummet after revealing that a Phase III study of its experimental antibiotic eravacycline missed key targets in a late stage trial.
Read More
Tag: eravacycline
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
